An Italian study on the tolerability of oral cannabis preparations found that CBDa has 18 times more bioavailability than CBD. The findings of this study show that, because of the overlapping benefits between CBD and CBDA, CBDA is 18 times more effective and, therefore, 18 times better value for money than CBD. While most people recognize CBD, CBDa is a relatively lesser-known cannabinoid. However, this particular cannabinoid, which happens to be a precursor to CBD, is gaining a lot of attention in medical communities because of its potential as a therapeutic agent.
So what is CBDa, how is it different from CBD, and should you try CBDa products? Below is a comprehensive guide that covers all of this and more. It is estimated that 113 cannabinoids can be found in hemp, with CBDA and CBD only two of them. Both CBDA and CBD are non-psychotropic cannabinoids, so they won't produce that euphoric feeling attributed to THC. While the characteristics of CBDA are similar to those found in CBD, CBDA has been shown to have a higher bioavailability than CBD, meaning that the body can absorb more amounts.
The increase in the oral use of whole hemp extract in veterinary and human medicine justifies further research on the native acid derivatives of CBD and THC, since existing products that are not thermally extracted contain CBDA and THCA. This is the first serum pharmacokinetic evaluation of cannabinoids and major metabolites using an extract derived from the whole hemp plant in dogs, especially for the main forms of cannabinoid acids, CBDA and THCA, which are not routinely evaluated. In fact, CBDa acts on 5-HT receptors in the same way as selective serotonin reuptake inhibitory antidepressants (SSRIs). Through this interaction, CBDa appears to be effective in treating nausea, which is particularly useful in cancer patients undergoing chemotherapy.
In animal studies, CBDa has been shown to reduce anxiety and expressions of anxiety-like behavior, while CBD interferes with the representation of symptoms of fear expression. Bioavailability is a subset of absorption; the percentage of an administered dose that reaches the systemic circulation. This suggests that CBDa might have more potent activity in the ECS, possibly due to the additional bioavailability of the cannabinoid. CBDA may not be as popular as CBD, but it's a crucial component of the hemp plant because without it, CBD wouldn't exist.
In general terms, the oral bioavailability of a drug is the percentage of the drug dose that eventually reaches the circulation and the therapeutic site of action. 24-hour seven-point pharmacokinetics of three hemp-based oral forms showing the oral absorption kinetics (mean and SEM) of cannabidiol (CBD blue), cannabidiolic acid (CBDA red), Δ9-tetrahydrocannabinol (THC green), tetrahydrocannabinolic acid (THCA purple) and 7-carboxycannabidiol (7-COOH-CBD) light blue for Form 2 and Form 3 only). Primarily, this cannabinoid has been recognized because it has exceptional bioavailability compared to CBD, which could make it a better agent for anxiety. Often, an orally administered drug is metabolized and eliminated before it actually reaches systemic blood circulation, so its bioavailability is 0%.
Many conjectures have been made about the bioavailability of CBD and CBDA in the literature, but few real studies. Some people make raw, uncured cannabis juices to benefit from CBDA, but there are products available that use raw hemp or offer a wide range of cannabinoids such as CBDA, along with terpenes and flavonoids found naturally in the plant. .
